-
-
@BioBoyScout's Equity Research Report and $81 PT on$ARWR challenging conventional thinking. Come see why it paved the way 3 months before all the others got there. https://bioboyscout.com/#RNAi#biotechhttps://finance.yahoo.com/news/bioboyscout-online-biotech-valuation-calculators-130038064.html … -
Today
$ARWR reported promising interim results from ongoing Ph1/2a studies of our cardiometabolic#RNAi candidates ARO-APOC3 being developed for severe#hypertriglyceridemia & ARO-ANG3 being developed for#dyslipidemias &#MetabolicDiseases. Learn more: http://bit.ly/3bdGvh7 pic.twitter.com/9o74TCFrKs
-
$ARWR Arrowhead reported interim clinical data on#RNAi-based cardiometabolic candidates ARO-APOC3 (n=3) and ARO-ANG3 (n=22). Company expects initiation of pivotal studies this year. PR: https://www.businesswire.com/news/home/20200205005824/en/Arrowhead-Reports-Interim-Clinical-Data-Cardiometabolic-Candidates …pic.twitter.com/Uh60X3CbyD
-
$ARWR interim results for ARO-APOC3 and ARO-ANG3 - just WOW!!!#RNAi#biotech#GameOnpic.twitter.com/liZBBeLrFZ
-
PK and PD of the Small Interfering Ribonucleic Acid (
#siRNA), Givosiran, in Patients with Acute Hepatic#Porphyria$ALNY$ARWR$DRNA$ABUS$SLN$AMGN@OliXPharmaceut1#RNAi@RNAi_papers@JMaraganore@Alnylam https://www.ncbi.nlm.nih.gov/pubmed/31994716 pic.twitter.com/X6jFMv339V
-
Our assays are suitable for the assessment of
#immunotoxicity to#RNAi therapeutics - agents which are scoring approval.@NatRevDrugDischttps://www.nature.com/articles/d41573-019-00209-2 … -
Expecting an update on all
$ARWR programs tomorrow, but especially the 4 they now show advancing in Phase on the pipeline. https://arrowheadpharma.com/pipeline/ APOC3 and ANG3 are now at PH2 while HSD and HIF2 are newly listed as phase 1 assets.#RNAi Progressing as expected -
Another very exciting paper from
@cecerelab on@biorxivpreprint. Thesis of@Pierq culminating in to this interesting article about role of Argonaute slicing of maternal mRNAs!#RNAi#MTZ#elegans. Check it out for more detailshttps://twitter.com/cecerelab/status/1224775821363228673 … -
Very excited to share our first preprint! Argonaute cleavage of maternal mRNAs in C. elegans embryos, check it out! Proud of
@Pierq and@cecerelab :) please send us your comments!#RNAi#MTZ#elegans#embryo#institutpasteur#argonautehttps://twitter.com/biorxivpreprint/status/1224464921603313669 … -
Tipbox picks its favorites from our 'Discovered: 20 years of breakthroughs' e-book. Which would you choose? https://bit.ly/2EchogK
#RNAi#CRISPR#5hmC -





maybe it’s time for #antibodies and#RNAi emojis as well :) -
Don't miss this Interview with the 2019 OTS Lifetime Achievement Award Winner Muthiah (Mano) Manoharan!
$ALNY$ARWR$DRNA$ABUS$SLN$AMGN@OliXPharmaceut1#siRNA#RNAi@RNAi_papers@JMaraganore@Alnylam@ArrowheadPharma@SilenceTheraPlc@DicernaPharma https://www.oligotherapeutics.org/interview-with-mano-manoharan/ …pic.twitter.com/0eS9Ww4w0I
-
Strange that
$ARWR has been selling off during#coronavirus scare as they likely have as much capability to address as anyone who has announced treatment development. https://sirnaomics.com/news/sirnaomics-advances-rnai-based-prophylactics-and-therapeutics-to-battle-sari-caused-by-2019-ncov/ … ARWR could potentially silence Spike protein using inhaled#RNAi to inhibit replication.Prikaži ovu nit -
Local press on Allstar
#UTAustin team engineering bee gut bacteria to engage#RNAi to defend against viruses and mites@NancyMoran15@spleonard1@barricklab@DaviesLab@CSSBatUT UT researchers take on honey bee declinehttps://www.statesman.com/news/20200130/ut-researchers-take-on-honey-bee-decline … -
We’re pleased to announce that we’ve received a positive opinion from the EMA (
@EMA_News) Committee for Medicinal Products for Human Use (#CHMP) for our investigational#RNAi therapeutic for the treatment of the#raredisease acute hepatic#porphyria. -
-
Plugging a 2019 article from
@nature https://www.nature.com/articles/d41586-019-03068-4 … beautifully explains RNA therapeutics#RNA#siRNA#ASO#RNAi#Science#research#Biotechnology
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.